FIBRONOX, INC

From the company

FibroNox has pioneered the development of patented first-in-class treatments to mitigate life-threatening fibrotic diseases, including selective Nox4 inhibitors and Nrf2 activators. Its small-molecules have demonstrated efficacy in preclinical studies for halting and reducing established fibrosis. The company focuses on idiopathic pulmonary fibrosis (IPF) as its primary indication, with preclinical data supporting other fibrotic indications, and is developing inhaled therapeutic delivery for pulmonary fibrosis.